title: Busulfan after HSCT in children and young adults - Authors' reply.
authors.affiliation: Department of Medicine, University of California San Francisco, CA, USA.
authors.forename: Imke H
authors.initials: IH
authors.lastname: Bartelink
authors.affiliation: Clinical Pharmacy Department, University Medical Center Utrecht, Utrecht, Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, Netherlands.
authors.forename: Arief
authors.initials: A
authors.lastname: Lalmohamed
authors.affiliation: Pediatric Allergy, Immunology, and Bone Marrow Transplantation Division and Department of Clinical Pharmacy, University of California San Francisco, CA, USA.
authors.forename: Janel R
authors.initials: JR
authors.lastname: Long-Boyle
authors.affiliation: Division of Pediatrics, Blood and Marrow Transplantation Program, University Medical Center Utrecht, Utrecht, Netherlands; Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands. Electronic address: j.j.boelens@umcutrecht.nl.
authors.forename: Jaap Jan
authors.initials: JJ
authors.lastname: Boelens
mesh_terms: D002066:Busulfan; D002648:Child; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D019172:Transplantation Conditioning; D055815:Young Adult
chemical_list: D002066:Busulfan